Mróz Robert M, Skopiński Tomasz, Hołownia Adam, Chyczewska Elżbieta, Braszko Jan J
Klinika Chorób Płuc i Gruźlicy Uniwersytetu Medycznego w Białymstoku.
Pneumonol Alergol Pol. 2011;79(1):32-8.
Currently available pharmacological treatment of COPD relies mostly on prophylaxis (smoking cessation) and symptomatic treatment, i.e. inhaled anticholinergic agents, β2-agonists and phosphodiesterase inhibitors, aiming in their bronchodilatation capacity. Inhaled corticosteroid therapy is mainly prescribed in far advanced stages of the disease and its role in disease modification is still controversial. The authors analize currently available treatment modalities with regards to their potential anti-inflammatory and pleiotropic mode of action, which may lead to disease course modification.
目前慢性阻塞性肺疾病(COPD)的药物治疗主要依赖于预防(戒烟)和对症治疗,即吸入抗胆碱能药物、β2受体激动剂和磷酸二酯酶抑制剂,利用它们的支气管扩张能力。吸入性糖皮质激素治疗主要用于疾病的晚期阶段,其在改变疾病进程方面的作用仍存在争议。作者分析了目前可用的治疗方式在潜在抗炎和多效性作用模式方面的情况,这可能会导致疾病进程的改变。